Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1212/NXI.0000000000000157 http://scihub22266oqcxt.onion/10.1212/NXI.0000000000000157 C4635549!4635549!26587553     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Neurol+Neuroimmunol+Neuroinflamm 2015 ; 2 (6): ä Nephropedia Template TP {{tp|p=26587553|t=2015. Myeloid cells as target of fingolimod action in multiple sclerosis |pdf=|usr=}}{{26587553}} gab.com Text Myeloid cells as target of fingolimod action in multiple sclerosis JO: Neurol Neuroimmunol Neuroinflamm http://www.kidney.de/pget.php?&tw=1&pmid=26587553 #FOAvip Objective:: To track the effects of fingolimod, an approved drug for multiple sclerosis (MS), on the activation of myeloid cells from the periphery to the CNS. Methods:: In vitro and ex vivo immunologic studies coupled with flow cytometry were performed to evaluate the action of fingolimod on lipopolysaccharide (LPS)?induced expression of activation markers in human monocytes from healthy participants, participants with untreated MS, and participants with fingolimod-treated MS. In vivo administration of fingolimod during experimental autoimmune encephalomyelitis (EAE) was established to verify the activation state of splenic, CNS infiltrating, and CNS resident myeloid cells ex vivo at flow cytometer. Results:: We found that in vitro exposure of human monocytes to fingolimod inhibited LPS-induced CD25 and CD150 expression and tumor necrosis factor?? (TNF-?) secretion without altering immune cell survival. Further, EAE treatment with fingolimod led to reduced amounts of TNF-? produced by myeloid cells in vivo in the spleen and CNS. Finally, while displaying normal induction of CD25 and CD150 levels at high LPS concentration, monocytes from patients with fingolimod-treated MS showed significantly higher activation threshold at suboptimal LPS stimulation than controls. Conclusions:: The inhibition of myeloid cell activation may be part of the immunosuppressive action of fingolimod and take place in the periphery and in the CNS. Twit Text FOAVip Myeloid cells as target of fingolimod action in multiple sclerosis ????Neurol Neuroimmunol Neuroinflamm http://www.kidney.de/pget.php?&tw=1&pmid=26587553 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26587553 #FOAvip English Wikipedia <ref>{{Cite pmid|26587553}}</ref> Myeloid cells as target of fingolimod action in multiple sclerosis #MMPMID26587553 Di Dario M; Colombo E; Govi C; De Feo D; Messina MJ; Romeo M; Sangalli F; Moiola L; Rodegher M; Martino G; Martinelli V; Comi G; Farina C Neurol Neuroimmunol Neuroinflamm 2015[Dec]; 2 (6): ä PMID26587553show ga Objective:: To track the effects of fingolimod, an approved drug for multiple sclerosis (MS), on the activation of myeloid cells from the periphery to the CNS. Methods:: In vitro and ex vivo immunologic studies coupled with flow cytometry were performed to evaluate the action of fingolimod on lipopolysaccharide (LPS)?induced expression of activation markers in human monocytes from healthy participants, participants with untreated MS, and participants with fingolimod-treated MS. In vivo administration of fingolimod during experimental autoimmune encephalomyelitis (EAE) was established to verify the activation state of splenic, CNS infiltrating, and CNS resident myeloid cells ex vivo at flow cytometer. Results:: We found that in vitro exposure of human monocytes to fingolimod inhibited LPS-induced CD25 and CD150 expression and tumor necrosis factor?? (TNF-?) secretion without altering immune cell survival. Further, EAE treatment with fingolimod led to reduced amounts of TNF-? produced by myeloid cells in vivo in the spleen and CNS. Finally, while displaying normal induction of CD25 and CD150 levels at high LPS concentration, monocytes from patients with fingolimod-treated MS showed significantly higher activation threshold at suboptimal LPS stimulation than controls. Conclusions:: The inhibition of myeloid cell activation may be part of the immunosuppressive action of fingolimod and take place in the periphery and in the CNS. äMyeloid cells as target of fingolimod action in multiple sclerosis (epmc).pdf DeepDyve Pubget Overpricing